US › Healthcare

Dermata Therapeutics Inc (DRMA)

US · Healthcare · Biotechnology

$0.86-5.49%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.0M

EPS

$-0.74

EPS estimate

$-0.55

EPS came in at -0.74 against a street estimate of -0.55 — a miss of 34.5%.

Key statistics

Market cap

$4.3M

Forward P/E

0.0

P/B

1.59

Book value

$0.87

EPS (TTM)

$-4.39

52-week high

$4.35

52-week low

$0.60

50-day MA

$1.23

200-day MA

$1.41

Beta

0.66

Analyst view

Analysts rate Dermata Therapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $4.00.

Shareholding

Insiders

27.35%

Institutions

7.77%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.41%
Welch & Forbes LLC	0.40%
State Street Corp	0.38%
UBS Group AG	0.34%
Susquehanna International Group, LLP	0.32%
XTX Topco Ltd	0.30%
Advisory Alpha, LLC	0.20%
Tower Research Capital LLC	0.08%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dermata Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.